Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Tools Developed for Early Meningitis Diagnosis

By LabMedica International staff writers
Posted on 28 Sep 2010
A predictive model based on two blood tests and a clinical sign will allow physicians assess whether or not a suspected case of meningitis is bacterial or viral in origin. More...


Bacterial meningitis is a serious infection of the fluid in the spinal cord and the fluid that surrounds the brain commonly caused by three types of bacteria: Haemophilus influenzae type b, Neisseria meningitidis, and Streptococcus pneumoniae bacteria. The diagnosis is usually made by growing the bacteria in culture from cerebral spinal fluid obtained from a lumbar puncture.

In a recent report from the UK Health Protection Agency's (HPA; London, UK) annual conference, analysis of data collected on 720 patients from all probable cases of bacterial and viral meningitis was presented. The patients had been admitted to participating hospitals in the South West, West Midlands and London regions of England. The date was collected from July 1, 2008 and June 30, 2009.

After examining the clinical symptoms, biochemistry and microbiology of 385 confirmed cases of meningitis over a 12 month period, the team identified three factors based on routine clinical assessment and early available laboratory test results that help differentiate between bacterial and viral meningitis. The results showed that the peripheral polymorphonuclear leukocyte (PMN) count, C-reactive protein level in the blood and rash are strongly associated with bacterial meningitis. Leukocyte PMN counts above 16 × 109/L, and a C-reactive protein level of more than 100 mg/L associated with a hemorrhagic rash, were most likely to be found in confirmed cases of bacterial meningitis. The normal PMN count varies with age, but the range is usually between 2.5 × 109/L to 7.5 × 109/L and a normal C-reactive protein is less than 10mg/L.

Oluwatoyin O. Ejidokun M.B. B.S., M.Sc., Ph.D.,, who led the study team, said, "While further testing needs to take place to test the accuracy of the model, this simple model offers the prospect of a rapid predictive tool to help clinical and public health management of suspected bacterial meningitis cases." Swift diagnosis of bacterial meningitis is crucial to protecting public health as it means potentially lifesaving interventions can be put in places, such as prescribing antibiotics to the patient and people they have been in contact with.
Related Links:
UK Health Protection Agency




Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Electrolyte Analyzer
BKE-B
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.